Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from CPRX

3 Pharmaceutical Stocks That Look Like Huge Bargains

Increasing investments in R&D and rising expenditure on healthcare are expected to bolster the pharmaceutical sector's growth. Therefore, we think the stocks of fundamentally sound pharmaceutical companies Bristol-Myers Squibb (BMY), Bayer Aktiengesellschaft (BAYRY), and Catalyst Pharmaceuticals, Inc. (CPRX), which are currently trading at huge discounts to their peers, could be…

StockNews.com

5 Pharmaceutical Stocks Under $10 to Buy Right Now

Supportive federal policies to boost medical research and development, tech integration, and robust demand are factors that are expected to drive the long-term growth of the pharmaceutical industry. Thus, we think it could be wise to bet on quality pharmaceutical stocks Catalyst Pharmaceuticals (CPRX), Radius Health (RDUS), Assertio Holdings (ASRT),…

StockNews.com

Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings

Piper Sandler raised the price target marginally on Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to $8.75 from $8.00, with an Overweight rating unchanged. Catalyst expects FY22 revenue of $195 million - $205 million, driven by transitioning ~125 patients previously on Ruzurgi onto Firdapse, analyst Joseph Catanzaro writes in a research note. Wall Street's estimate for sales…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) anticipates

Benzinga

Catalyst Pharmaceuticals: A Biotech Stock Worth Owning

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) has been advancing with the help of its product, FIRDAPSE. Furthermore, its top and bottom line grew in its last reported quarter. So, let’s discuss in detail why it could be wise to add CPRX to one’s portfolio now. Read on.

StockNews.com

1 2

Organisations

BristolMyers Squibb Company

95 stories

Medical – Pharmaceuticals

Catalyst Pharmaceuticals

26 stories

ASRT

19 stories

Assertio Holdings Inc

17 stories

Catalyst Pharmaceuticals Inc

Bayer Aktiengesellschaft

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.